The bold sections from the top post are actually bolded on the Philips site. Let's take a look at those bold parts again and my thoughts on how they relate to PCK. Most of this will be known by us who have been in PCK for a time, but new folks are always dropping by. Please forgive me if some of this seems obvious.
15 top companies from around the world were selected to join our exclusive and intense 12-week program Philips, a top three global healthcare provider sees PCK as one of the top 15 companies globally in terms of potential in the healthtech field.
Identify, validate and shape collaboration opportunities between the selected companies and Philips Philips is actively seeking to collaborate with those 15 companies should it be suitable for Philips.
Our Programs are themed on health technology areas where together with startups and small businesses we can make a difference PCK is a small business but can make a difference hence more potential.
Our patient monitoring solutions monitor more than 275 million people every year Philips are huge. PCK is also in the health monitoring business. Self-explanatory.
Leadership in telehealth technology Philips always looks to take the lead globally in the field, and part of leading in the field is identifying opportunities for acquisition, collaboration etc.
AI as encompassing big data, machine learning, and predictive analytics PCK utilises all of those.
New AI capabilities PCK is also trialling the children's app currently, looking to develop new capabilities.
Regulatory changes Australian government funding. Royal commission. A shift towards a more home based care approach, perhaps especially in the USA where healthcare costs are obscene. Painchek Family Carer: "A subscription to PainChek® is available to family carers that are receiving support from a professional Home Care Operator with a PainChek® Shared Care License." https://www.painchekfamilycarer.com/
Transforming business models Painchek is a SaaS (software as a service) dementia patient pain assessment tool. A world first, transformative innovation that currently has a monopoly in its specific arena. Many companies will want a strategic partnership.
The demand for benchmarking Painchek has already generated a large amount of robust clinical data elements, and with the Australian government roll-out this will increase dramatically. The value of this data should not be underestimated.
PCK Price at posting:
33.0¢ Sentiment: Buy Disclosure: Held
